Results 121 to 130 of about 15,191 (179)
Chemotherapy management of a pediatric B-ALL patient with moyamoya disease: a case report. [PDF]
Front OncolCheng YR, Han J, Huang ZY, Qu P, Zhou F.
europepmc +1 more source
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. [PDF]
Blood AdvFaulk KE +14 more
europepmc +1 more source
Extranodal NK/T-Cell Lymphoma in the Nasal Region Illustrating the Differential Diagnosis of Lesions of the Face. [PDF]
Clin Case RepDias L +5 more
europepmc +1 more source
The impact of asparaginase phenotype-related single nucleotide polymorphisms on prognosis in pediatric B-cell precursor acute lymphoblastic leukemia. [PDF]
Eur J Med ResZhang J +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2007
L-asparaginases have been established components in the treatment of acute leukemias for nearly 40 years. Their antitumor effect results from the depletion of asparagine, an amino acid essential to leukemic cells, and subsequent inhibition of protein synthesis leading to considerable cytotoxicity.
Cecilia H, Fu, Kathleen M, Sakamoto
openaire +2 more sources
L-asparaginases have been established components in the treatment of acute leukemias for nearly 40 years. Their antitumor effect results from the depletion of asparagine, an amino acid essential to leukemic cells, and subsequent inhibition of protein synthesis leading to considerable cytotoxicity.
Cecilia H, Fu, Kathleen M, Sakamoto
openaire +2 more sources
Leukemia & Lymphoma, 2011
Asparaginase is one of the main drugs used to treat acute lymphoblastic leukemia and certain non-Hodgkin lymphomas. The drug is a bacterial product, and this results in differences in activity, efficacy, and side effects among the various marketed products. Native products originate from either Escherichia coli or Erwinia chrysanthemi.
openaire +2 more sources
Asparaginase is one of the main drugs used to treat acute lymphoblastic leukemia and certain non-Hodgkin lymphomas. The drug is a bacterial product, and this results in differences in activity, efficacy, and side effects among the various marketed products. Native products originate from either Escherichia coli or Erwinia chrysanthemi.
openaire +2 more sources
[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2016To determine the pharmacokinetics and bioequivalence of self-assembled hyaluronic acid-graft-poly (ethylene glycol)/hydroxypropyl-beta-cyclodextrin hollow nanospheres loaded with asparaginase (AHHPs) in SD rats.AHHPs were prepared and observed under transmission electron microscopy.
Zi-jun, Yan +5 more
openaire +1 more source